A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy
The main purpose of this study is to measure the safety and efficacy of LY3209590 compared with insulin degludec in participants with type 1 diabetes treated with multiple daily injection therapy.
• Have a clinical diagnosis of type 1 diabetes for at least 1 year prior to screening
• Have received treatment with basal-bolus insulin analog multiple daily injection therapy according to the local product label for at least 90 days prior to screening
• Have an HbA1c value of 7.0% to 10.0%, inclusive, as determined by the central laboratory at screening.
• Have a body mass index of ≤35 kilogram/square meter (kg/m²)